Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Heart Test announces further internationalization of patent portfolio » 09:02
02/03/23
02/03
09:02
02/03/23
09:02
HSCS

Heart Test Laboratories

$1.42 /

-0.51 (-26.42%)

Heart Test Laboratories,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HSCS Heart Test Laboratories
$1.42 /

-0.51 (-26.42%)

HSCS Heart Test Laboratories
$1.42 /

-0.51 (-26.42%)

01/30/23 Ascendiant
Heart Test Laboratories initiated with a Buy at Ascendiant
12/19/22 Maxim
HeartSciences price target lowered to $3 from $8 at Maxim
11/09/22 Maxim
HeartSciences initiated with a Buy at Maxim
08/08/22 Benchmark
HeartSciences initiated with a Speculative Buy at Benchmark
HSCS Heart Test Laboratories
$1.42 /

-0.51 (-26.42%)

Hot Stocks
Greenland Technologies regains compliance with Nasdaq listing rules » 08:02
02/03/23
02/03
08:02
02/03/23
08:02
GTEC

Greenland Technologies

$2.54 /

+0.05 (+2.01%)

Greenland Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTEC Greenland Technologies
$2.54 /

+0.05 (+2.01%)

05/18/22 Litchfield Hills
Greenland Technologies initiated with a Buy at Litchfield Hills
Yesterday
On The Fly
Here's What You Missed in Cannabis This Week » 11:29
02/02/23
02/02
11:29
02/02/23
11:29
IGC

India Globalization Capital

/

+

, TLRY

Tilray

$3.50 /

+0.16 (+4.80%)

, STMH

Stem Holdings

/

+

, INCR

InterCure

$3.81 /

+0.11 (+2.97%)

, HITI

High Tide

$1.60 /

+0.04 (+2.56%)

, FLGC

Flora Growth

/

+

, GNLN

Greenlane

/

+

, AYRWF

Ayr Wellness

$1.34 /

+0.059 (+4.61%)

, ACB

Aurora Cannabis

$1.14 /

+0.055 (+5.07%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.15 /

+0.08 (+2.61%)

, CRON

Cronos Group

$2.59 /

+0.065 (+2.58%)

, CANN

Trees Corporation

/

+

, GDNSF

Goodness Growth

/

+

, GTBIF

Green Thumb Industries

$8.45 /

+0.39 (+4.84%)

, TCNNF

Trulieve Cannabis

$6.75 /

+0.00599 (+0.09%)

, ZYNE

Zynerba

/

+

, ATAI

Atai Life Sciences

$1.90 /

+0.05 (+2.70%)

, CMPS

Compass Pathways

$10.74 /

+0.1 (+0.94%)

, RLMD

Relmada Therapeutics

$4.31 /

+0.05 (+1.17%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

TCNNF Trulieve Cannabis
$6.75 /

+0.00599 (+0.09%)

STMH Stem Holdings
/

+

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.60 /

+0.04 (+2.56%)

GTBIF Green Thumb Industries
$8.45 /

+0.39 (+4.84%)

GNLN Greenlane
/

+

GDNSF Goodness Growth
/

+

FLGC Flora Growth
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

CANN Trees Corporation
/

+

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

IGC India Globalization Capital
/

+

11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
TLRY Tilray
$3.50 /

+0.16 (+4.80%)

01/10/23 MKM Partners
Tilray price target lowered to $3 from $4 at MKM Partners
01/10/23 Canaccord
Tilray price target lowered to $5 from $7 at Canaccord
01/09/23 Alliance Global Partners
Tilray price target lowered to $3 from $4 at Alliance Global Partners
12/28/22 Piper Sandler
Tilray estimates lowered on softer beer sales at Piper Sandler
STMH Stem Holdings
/

+

INCR InterCure
$3.81 /

+0.11 (+2.97%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
HITI High Tide
$1.60 /

+0.04 (+2.56%)

FLGC Flora Growth
/

+

12/19/22 Alliance Global Partners
Flora Growth price target lowered to $1.25 from $2 at Alliance Global Partners
10/24/22 Alliance Global Partners
Flora Growth price target lowered to $2 from $2.50 at Alliance Global Partners
09/23/22 Alliance Global Partners
Flora Growth initiated with a Buy at Alliance Global Partners
08/01/22 Cantor Fitzgerald
Cantor starts Flora Growth with Neutral amid diversification process
GNLN Greenlane
/

+

11/16/22 Alliance Global Partners
Greenlane price target lowered to $2 from $6 at Alliance Global Partners
11/01/22 Roth MKM
Greenlane downgraded to Neutral from Buy at Roth Capital
08/17/22 Alliance Global Partners
Greenlane price target raised to $6 from $1.50 at Alliance Global Partners
08/17/22 Canaccord
Greenlane price target lowered to $5 from $20 at Canaccord
AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

01/30/23 Canaccord
Ayr Wellness downgraded to Speculative Buy from Buy at Canaccord
10/28/22 BTIG
Ayr Wellness initiated with a Buy at BTIG
08/19/22 Canaccord
Ayr Wellness price target lowered to C$30 from C$40 at Canaccord
08/19/22 Northland
Ayr Wellness price target lowered to $10 from $14 at Northland
ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

01/27/23 Stifel
Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel
12/28/22 Piper Sandler
Aurora Cannabis price target lowered to $1 from $2 at Piper Sandler
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
CVSI CV Sciences
/

+

CTST CannTrust
/

+

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

02/01/23 CIBC
Canopy Growth price target lowered to C$2.50 from C$3 at CIBC
11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

11/08/22 Canaccord
Cronos Group price target lowered to C$4.75 from C$5 at Canaccord
11/01/22 Bernstein
Cronos started with Market Perform on limited visibility at Bernstein
11/01/22 Bernstein
Cronos Group initiated with a Market Perform at Bernstein
CANN Trees Corporation
/

+

GDNSF Goodness Growth
/

+

11/16/22 Canaccord
Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord
10/14/22 Alliance Global Partners
Verano Holdings price target lowered to C$12 from C$16 at Alliance Global
05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
GTBIF Green Thumb Industries
$8.45 /

+0.39 (+4.84%)

12/01/22 Wedbush
Wedbush starts Green Thumb with Outperform, names top cannabis pick
12/01/22 Wedbush
Green Thumb Industries initiated with an Outperform at Wedbush
11/03/22 Stifel
Green Thumb Industries price target raised to C$31 from C$30.50 at Stifel
TCNNF Trulieve Cannabis
$6.75 /

+0.00599 (+0.09%)

12/01/22 Wedbush
Wedbush starts Trulieve with Outperform on broadening reach
12/01/22 Wedbush
Trulieve Cannabis initiated with an Outperform at Wedbush
11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
ZYNE Zynerba
/

+

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

01/19/23 H.C. Wainwright
Atai Life Sciences price target lowered to $20 from $50 at H.C. Wainwright
01/09/23 Canaccord
Atai Life Sciences price target lowered to $11 from $27 at Canaccord
01/09/23 Loop Capital
Atai Life Sciences price target lowered to $10 from $18 at Loop Capital
01/09/23 Citi
Atai Life Sciences price target lowered to $10 from $20 at Citi
CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

12/15/22 EF Hutton
Compass Pathways initiated with a Buy at EF Hutton
12/09/22 Oppenheimer
Compass Pathways price target lowered to $33 from $55 at Oppenheimer
11/01/22 Loop Capital
Compass Pathways initiated with a Buy at Loop Capital
RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

12/08/22 Truist
Relmada Therapeutics price target lowered to $4 from $7 at Truist
11/11/22 SVB Securities
Relmada 'still has a chance' for positive depression data, says SVB
10/14/22 BofA
Axsome shares could react positively to Relmada trial failure, says BofA
10/14/22 Goldman Sachs
Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs
ZYNE Zynerba
/

+

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

HITI High Tide
$1.60 /

+0.04 (+2.56%)

GNLN Greenlane
/

+

FLGC Flora Growth
/

+

CRON Cronos Group
$2.59 /

+0.065 (+2.58%)

CMPS Compass Pathways
$10.74 /

+0.1 (+0.94%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

  • 27
    May
IGC India Globalization Capital
/

+

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

IGC India Globalization Capital
/

+

HITI High Tide
$1.60 /

+0.04 (+2.56%)

FLGC Flora Growth
/

+

AYRWF Ayr Wellness
$1.34 /

+0.059 (+4.61%)

ATAI Atai Life Sciences
$1.90 /

+0.05 (+2.70%)

TLRY Tilray
$3.50 /

+0.16 (+4.80%)

RLMD Relmada Therapeutics
$4.31 /

+0.05 (+1.17%)

INCR InterCure
$3.81 /

+0.11 (+2.97%)

CGC Canopy Growth
$3.15 /

+0.08 (+2.61%)

ACB Aurora Cannabis
$1.14 /

+0.055 (+5.07%)

Wednesday
Syndicate
1847 Holdings files to sell 7.93M shares of common stock for holders  16:48
02/01/23
02/01
16:48
02/01/23
16:48
EFSH

1847 Holdings

$1.85 /

-0.04 (-2.12%)

 
ShowHide Related Items >><<
EFSH 1847 Holdings
$1.85 /

-0.04 (-2.12%)

EFSH 1847 Holdings
$1.85 /

-0.04 (-2.12%)

Syndicate
1847 Holdings files $150M mixed securities shelf  16:39
02/01/23
02/01
16:39
02/01/23
16:39
EFSH

1847 Holdings

$1.85 /

-0.04 (-2.12%)

 
ShowHide Related Items >><<
EFSH 1847 Holdings
$1.85 /

-0.04 (-2.12%)

EFSH 1847 Holdings
$1.85 /

-0.04 (-2.12%)

Hot Stocks
MamaMancini's appoints Adam Michaels as chairman of the board » 08:38
02/01/23
02/01
08:38
02/01/23
08:38
MMMB

MamaMancini’s

$2.00 /

+0.015 (+0.76%)

MamaMancini's…

MamaMancini's Holdings announced the appointment of CEO Adam Michaels as Chairman, effective February 1, 2023, concurrent with the retirement of Carl Wolf.

ShowHide Related Items >><<
MMMB MamaMancini’s
$2.00 /

+0.015 (+0.76%)

Hot Stocks
Agile Therapeutics provides clinical update on Twirla, pipeline evaluation » 08:06
02/01/23
02/01
08:06
02/01/23
08:06
AGRX

Agile Therapeutics

/

+

Agile Therapeutics…

Agile Therapeutics provided an update on the Twirla post-marketing studies and status of its ongoing evaluation of the Company's pipeline. Twirla Post-Marketing Studies: As part of Twirla's approval, the United States Food and Drug Administration required the Company to conduct a long-term prospective, multi-center clinical post-marketing requirement study comparing the risks of venous thromboembolism and arterial thromboembolism in new users of Twirla to new users of combined hormonal contraceptives and Ortho Evra generic patches. In January 2023, the FDA agreed with the Company's proposal to address this PMR using electronic health records and insurance claims from a large database from multiple healthcare systems. The FDA also agreed to extend the study timelines. Under these new milestones, interim safety data reporting to the FDA is due in November 2029, and the final PMR study report is scheduled to be submitted to the FDA in November 2035. Status of Pipeline Evaluation: As previously disclosed, all work on Agile's pipeline has been halted since 2021 as the Company concentrates its efforts the commercialization of Twirla. Commercializing Twirla remains the Company's primary focus into 2023; however, the Company has continued to evaluate the potential eventual advancement of the AG200-15 Extended Regimen and the progestin-only patch. "Our primary focus since the launch of Twirla has been the commercial growth of Twirla. We believe, however, that we have potential value in our pipeline and have been evaluating how to prioritize the eventual development of our product candidates. While we do not currently expect to invest significant funds in our pipeline in 2023 as we continue to focus on maintaining capital efficiency and keeping tight control on our operating expenses, we have been using creative approaches to advance the evaluation of our pipeline and prepare for a time when we can move forward," stated, Al Altomari, Chairman and Chief Executive Officer of Agile Therapeutics.As part of its evaluation of the AG200-15 Extended Regimen, Agile performed an analysis with a simulated pharmacokinetic model that was used to predict the systemic levonorgestrel and ethinyl estradiol exposure of Twirla if used for twelve consecutive weeks. Data from a previously published clinical phase 1, open-label, randomized clinical trial2 was used for the PK model simulation, which included 36 healthy individuals who used a standard Twirla regimen for three consecutive weeks.

ShowHide Related Items >><<
AGRX Agile Therapeutics
/

+

AGRX Agile Therapeutics
/

+

12/30/22 H.C. Wainwright
Agile Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
07/26/22 Maxim
Agile Therapeutics upgraded to Buy from Hold at Maxim
07/11/22 H.C. Wainwright
H.C. Wainwright doubles Agile Therapeutics target on overturning of Roe
04/08/22 Maxim
Agile Therapeutics downgraded to Hold from Buy at Maxim
AGRX Agile Therapeutics
/

+

Tuesday
Hot Stocks
Hillstream BioPharma signs option agreement with Dana-Farber Cancer Institute » 07:17
01/31/23
01/31
07:17
01/31/23
07:17
HILS

Hillstream BioPharma

/

+

Hillstream BioPharma…

Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream's Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis. This approach combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long term responses and cures. "We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber," said Randy Milby, CEO of Hillstream. "This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients."

ShowHide Related Items >><<
HILS Hillstream BioPharma
/

+

Monday
Hot Stocks
Trust Stamp announces latest addition to its low-code orchestration platform » 08:37
01/30/23
01/30
08:37
01/30/23
08:37
IDAI

Trust Stamp

/

+

Trust Stamp announces…

Trust Stamp announces that it has integrated the Driver License Data Verification, DLDV, System, offered by the American Association of Motor Vehicle Administrators, AAMVA, into its low code orchestration platform. Now through its low-code solution, Trust Stamp provides commercial and government entities with the real-time capability to verify drivers license/ID information against data from the issuing agency. Trust Stamp has added 24 new customers to its low-code solution since it launched in February 2022. These new customers include 22 banks with over 850 of branches. Trust Stamp President, Andrew Gowasack, said, "As a result of growing fraud losses and unprecedented economic conditions, we are seeing banks focusing on increasing deposits and reevaluating their online enrollment processes. Onboarding must be simple and fast for genuine customers, but difficult for fraudsters who seek to exploit these streamlined processes."

ShowHide Related Items >><<
IDAI Trust Stamp
/

+

IDAI Trust Stamp
/

+

12/09/22 Maxim
Trust Stamp initiated with a Buy at Maxim
Initiation
Genprex initiated with a Buy at Dawson James » 07:51
01/30/23
01/30
07:51
01/30/23
07:51
GNPX

Genprex

$1.34 /

+0.03 (+2.29%)

Dawson James analyst…

Dawson James analyst Jason Kolbert initiated coverage of Genprex with a Buy rating and $3 price target. The company's oncology platform utilizes a non-viral Nanoparticle Delivery System and its lead program in oncology, REQORSA Immunogene Therapy, or GPX-001, has been shown to be complementary with targeted drugs and immunotherapies, the analyst tells investors in a research note. REQORSA is currently enrolling clinical patients in two trials initially exploring its utility in NSCLC with a range of agents and the FDA has granted Fast Track Designation for both trials, the firm noted. The company also has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells and its planned phase 1 trial "represents the first-ever gene therapy tested in humans for diabetes," Dawson James said.

ShowHide Related Items >><<
GNPX Genprex
$1.34 /

+0.03 (+2.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.